• Users Online: 246
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 
Year : 2022  |  Volume : 42  |  Issue : 3  |  Page : 134-137

Cellular immunotherapy with immune killer cells for treating a lung cancer patient with liver metastasis

Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan

Correspondence Address:
Dr. Chih-Feng Chian
114 No. 325, Sec. 2, Cheng-Gong Road, Neihu 114, Taipei
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmedsci.jmedsci_384_20

Rights and Permissions

Lung cancer has the highest number of deaths globally. About 75% of nonsmall cell lung cancer (NSCLC) cases are diagnosed at an advanced stage. Despite significant therapeutic progress, the prognosis remains poor. For patients who have undergone conventional treatment followed by disease progression, palliative care generally remains the only option. As reported in recent years, cellular immunotherapies play an important role in treating lung cancer and may be an option for terminal-stage disease. We applied a novel management approach with immune killer cells therapy to treat a patient with NSCLC with liver metastases. The carcinoembryonic antigen returned to normal level during the treatment period, and the follow-up abdominal computed tomography at 3 months after completion of the therapy displayed no residual metastatic liver tumors.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded184    
    Comments [Add]    

Recommend this journal